November 1, 2023

AI Technology Helps Geisinger in Fight Against Lung Cancer

DANVILLE, Pa. – Geisinger has begun using a new patient management system to expand its ability to identify and manage patients with incidentally identified lung abnormalities, as well as manage those eligible for lung cancer screening.

Nationally, incidental abnormalities are found about 40% of the time during imaging tests that are unrelated to the reason the test was ordered. In 2020, Geisinger implemented the STAIR™ Program (which stands for System to Track Abnormalities of Importance Reliably) to help manage these patients. If an incidental lung abnormality is found, the provider refers the patient to the STAIR team, which evaluates the patient and establishes a care plan.

About Eon

Eon is a healthcare technology company focused on supporting health systems in the identification and ongoing management of patients at risk of cancer and other lifethreatening conditions. Powered by condition-specific clinical AI, Eon’s longitudinal care management platform extracts incidental findings documented in radiology reports and helps ensure patients receive timely, guideline-based follow-up and remain in appropriate surveillance over time.

More than 70 health systems across over 1,200 facilities rely on Eon and its care management services to scale early detection programs, enable earlier diagnosis and treatment, and support sustained patient engagement—outcomes that also carry meaningful financial implications for health systems